CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 140 filers reported holding CLOVIS ONCOLOGY INC in Q1 2016. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $590,000 | -12.1% | 291,900 | +17.9% | 0.00% | – |
Q4 2021 | $671,000 | -31.2% | 247,500 | +13.1% | 0.00% | -100.0% |
Q3 2021 | $976,000 | -23.1% | 218,900 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $1,270,000 | -5.6% | 218,900 | +14.2% | 0.00% | 0.0% |
Q1 2021 | $1,346,000 | +50.2% | 191,700 | +2.7% | 0.00% | 0.0% |
Q4 2020 | $896,000 | -17.6% | 186,600 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $1,088,000 | -13.7% | 186,600 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $1,260,000 | +284.1% | 186,600 | +123.3% | 0.00% | – |
Q3 2019 | $328,000 | -73.6% | 83,550 | 0.0% | 0.00% | -100.0% |
Q2 2019 | $1,242,000 | -45.2% | 83,550 | -8.4% | 0.00% | -50.0% |
Q1 2019 | $2,265,000 | +42.5% | 91,250 | +3.2% | 0.00% | 0.0% |
Q4 2018 | $1,589,000 | -37.9% | 88,450 | +1.6% | 0.00% | -33.3% |
Q3 2018 | $2,557,000 | -32.8% | 87,050 | +4.1% | 0.00% | -25.0% |
Q2 2018 | $3,804,000 | -10.9% | 83,650 | +3.5% | 0.00% | -20.0% |
Q1 2018 | $4,269,000 | -20.6% | 80,850 | +2.3% | 0.01% | -16.7% |
Q4 2017 | $5,375,000 | -14.7% | 79,050 | +3.4% | 0.01% | -14.3% |
Q3 2017 | $6,299,000 | -12.0% | 76,450 | 0.0% | 0.01% | -12.5% |
Q2 2017 | $7,158,000 | +74.4% | 76,450 | +18.6% | 0.01% | +60.0% |
Q1 2017 | $4,104,000 | +62.2% | 64,450 | +13.2% | 0.01% | +25.0% |
Q4 2016 | $2,530,000 | +32.3% | 56,950 | +7.4% | 0.00% | +33.3% |
Q3 2016 | $1,912,000 | +153.2% | 53,050 | -3.6% | 0.00% | +200.0% |
Q2 2016 | $755,000 | -16.6% | 55,050 | +12.7% | 0.00% | -50.0% |
Q1 2016 | $905,000 | -33.6% | 48,850 | +25.6% | 0.00% | -33.3% |
Q4 2015 | $1,362,000 | -61.9% | 38,900 | 0.0% | 0.00% | -66.7% |
Q3 2015 | $3,577,000 | +36.6% | 38,900 | +30.5% | 0.01% | +28.6% |
Q2 2015 | $2,619,000 | +42.3% | 29,800 | +20.2% | 0.01% | +40.0% |
Q1 2015 | $1,841,000 | +34.2% | 24,800 | +1.2% | 0.01% | 0.0% |
Q4 2014 | $1,372,000 | +26.6% | 24,500 | +2.5% | 0.01% | +25.0% |
Q3 2014 | $1,084,000 | +7.8% | 23,900 | -1.6% | 0.00% | 0.0% |
Q2 2014 | $1,006,000 | -36.8% | 24,300 | +5.7% | 0.00% | -33.3% |
Q1 2014 | $1,593,000 | +46.0% | 23,000 | +27.1% | 0.01% | +50.0% |
Q4 2013 | $1,091,000 | +36.0% | 18,100 | +37.1% | 0.00% | +33.3% |
Q3 2013 | $802,000 | +23.4% | 13,200 | +36.1% | 0.00% | 0.0% |
Q2 2013 | $650,000 | – | 9,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |